The research progress of miRNA and diabetic peripheral neuropathy

doi:10.3877/cma.j.issn.2095-655X.2021.04.016

Abstract

Abstract:

Diabetic peripheral neuropathy (DPN) is one of the common complications of diabetes, with clinical manifestations including limb pain, numbness, paresthesia and ulceration. DPN is the main cause of non-traumatic amputation. MicroRNA (miRNA) belongs to non-coding RNA (ncRNA) and is an evolutionarily highly conservative RNA, usually 18-25 bases in length. MiRNA has been reported one after another by regulating the roles of multiple genes in a variety of diseases and cell types, such as cell growth, proliferation, differentiation, apoptosis, posttranscriptional gene regulation, and others. Studies have found that miRNA is closely related to nerve conduction, injury, and apoptosis, so miRNA can be used as biomarkers for the diagnosis and prognosis of DPN and as targets for potential molecular therapy. This article mainly reviews the role of miRNA in DPN and the related research progress based on miRNA therapy.

Key words: Diabetic neuropathies, Diabetes mellitus, microRNA, Biological markers

Chang Su, Qiuhua Liang, Lin Sun. The research progress of miRNA and diabetic peripheral neuropathy[J]. Chinese Journal of Diagnostics(Electronic Edition), 2021, 09(04): 285-288.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2021.04.016

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2021/V09/I04/285

References 37

[1]	付煊，高晖，阿米娜，等.2型糖尿病患者血糖水平及血糖变异性与糖化血红蛋白水平的相关性研究[J/CD]．中华诊断学电子杂志，2020，8(4)：242-247.
[2]	Eberle C, Stichling S．Clinical improvements by telemedicine interventions managing type 1 and type 2 diabetes: systematic meta-review[J]．J Med Internet Res，2021，23(2)：e23244.
[3]	Nguyen N, Takemoto JK.A case for alpha-lipoic acid as an alternative treatment for diabetic polyneuropathy[J]．J Pharm Pharm Sci，2018，21(1s)：177s-191s.
[4]	Lee KA, Park TS, Jin HY.Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy[J]．Endocrine，2020，70(3)：465-478.
[5]	Zhang X, Gong X, Han S，et al.MiR-29b protects dorsal root ganglia neurons from diabetic rat[J]．Cell BiochemBiophys，2014，70(2)：1105-1111.
[6]	Jia L, Wang L, Chopp M，et al.MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions[J]．Neuroscience，2016(329)：43-53.
[7]	Pop-Busui R, Boulton AJ, Feldman EL，et al.Diabetic neuropathy：a position statement by the American diabetes association[J]．Diabetes Care，2017，40(1)：136-154.
[8]	Sala D, Zorzano A．Differential control of muscle mass in type 1 and type 2 diabetes mellitus[J]．Cell Mol Life Sci，2015，72(20)：3803-3817.
[9]	Papanas N, Ziegler D．Risk factors and comorbidities in diabetic neuropathy: an update 2015[J]．Rev Diabet Stud，2015，12(1-2)：48-62.
[10]	Obrosova IG, Van Huysen C, Fathallah L，et al.An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function，metabolism，and antioxidative defense[J]．FASEB J，2002，16(1)：123-125.
[11]	Vincent AM, Feldman EL. New insights into the mechanisms of diabetic neuropathy[J]．Rev Endocr Metab Disord，2004，5(3)：227-236.
[12]	Vincent AM, Hayes JM, McLean LL，et al.Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1[J]．Diabetes，2009，58(10)：2376-2385.
[13]	Zhou H, Zhang W. Gene expression profiling reveals candidate biomarkers and probable molecular mechanism in diabetic peripheral neuropathy[J]．Diabetes Metab Syndr Obes，2019(12)：1213-1223.
[14]	Bönhof GJ, Herder C, Strom A，et al.Emerging biomarkers，tools，and treatments for diabetic polyneuropathy[J]．Endocr Rev，2019，40(1)：153-192.
[15]	Hoffmann M, Kujath P, Flemming A, et al. Survival of diabetes patients with major amputation is comparable to malignant disease[J]．Diab Vasc Dis Res，2015，12(4)：265-271.
[16]	Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes[J]．JAMA，2005，293(2)：217-228.
[17]	Mitchelson KR, Qin WY.Roles of the canonical myomiRs miR-1，-133 and -206 in cell development and disease[J]．World J Biol Chem，2015，6(3)：162-208.
[18]	Duong Van Huyen JP, Tible M, Gay A，et al.MicroRNAs as non-invasive biomarkers of heart transplant rejection[J]．Eur Heart J，2014，35(45)：3194-3202.
[19]	Kozomara A, Griffiths-Jones S．MiRBase：annotating high confidence microRNAs using deep sequencing data[J]．Nucleic Acids Res，2014，42(Database issue)：D68-D73.
[20]	Lewis BP, Burge CB, Bartel DP.Conserved seed pairing，often flanked by adenosines，indicates that thousands of human genes are microRNA targets[J]．Cell，2005，120(1)：15-20.
[21]	Osmai M, Osmai Y, Bang-Berthelsen CH, et al. MicroRNAs as regulators of beta-cell function and dysfunction[J]．Diabetes Metab Res Rev，2016，32(4)：334-349.
[22]	Duksal T, Tiftikcioglu BI, Bilgin S，et al.Role of inflammation in sensory neuropathy in prediabetes or diabetes[J]．Acta Neurol Scand，2016，133(5)：384-390.
[23]	Bai X, Zhang J, Cao M，et al.MicroRNA-146a protects against LPS-induced organ damage by inhibiting Notch1 in macrophage[J]．Int Immunopharmacol，2018(63)：220-226.
[24]	Thakkar S, Wang X, Khaidakov M, et al. Structure-based design targeted at LOX-1，a receptor for oxidized low-density lipoprotein[J]．Sci Rep，2015(5)：16740.
[25]	Liu XS, Fan B, Szalad A，et al.MicroRNA-146a mimics reduce the peripheral neuropathy in type 2 diabetic mice[J]．Diabetes，2017，66(12)：3111-3121.
[26]	Tardito S, Martinelli G, Soldano S，et al.Macrophage M1/M2 polarization and rheumatoid arthritis：a systematic review[J]．Autoimmun Rev，2019，18(11)：102397.
[27]	Ren W, Xi G, Li X，et al.Long non-coding RNA HCG18 promotes M1 macrophage polarization through regulating the miR-146a/TRAF6 axis，facilitating the progression of diabetic peripheral neuropathy[J]．Mol Cell Biochem，2021，476(1)：471-482.
[28]	Meza-Sosa KF, Pedraza-Alva G, Pérez-Martínez L．MicroRNAs：key triggers of neuronal cell fate[J]．Front Cell Neurosci，2014(8)：175.
[29]	Zhang Y, Song C, Liu J, et al. Inhibition of miR-25 aggravates diabetic peripheral neuropathy[J]．Neuroreport，2018，29(11)：945-953.
[30]	Li H, Zhu X, Zhang J, et al. MicroRNA-25 inhibits high glucose-induced apoptosis in renal tubular epithelial cells via PTEN/AKT pathway[J]．Biomed Pharmacother，2017(96)：471-479.
[31]	Wang C, Xu X, Chen J, et al. The construction and analysis of lncRNA-miRNA-mRNA competing endogenous RNA network of schwann cells in diabetic peripheral neuropathy[J]．Front Bioeng Biotechnol，2020(8)：490.
[32]	Gregory PA, Bert AG, Paterson EL，et al.The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1[J]．Nat Cell Biol，2008，10(5)：593-601.
[33]	Kurashige J, Kamohara H, Watanabe M, et al. MicroRNA-200b regulates cell proliferation，invasion，and migration by directly targeting ZEB2 in gastric carcinoma[J]．Ann Surg Oncol，2012，19 (Suppl 3)：S656-S664.
[34]	Lewin GR, Lechner SG, Smith ES.Nerve growth factor and nociception：from experimental embryology to new analgesic therapy[J]．Handb Exp Pharmacol，2014(220)：251-282.
[35]	Zhang Y, Chopp M, Liu XS，et al.MicroRNAs in the axon locally mediate the effects of chondroitin sulfate proteoglycans and cGMP on axonal growth[J]．Dev Neurobiol，2015，75(12)：1402-1419.
[36]	Jia L, Wang L, Chopp M，et al.MiR-29c/PRKCI regulates axonal growth of dorsal root ganglia neurons under hyperglycemia[J]．Mol Neurobiol，2018，55(1)：851-858.
[37]	Chentli F, Azzoug S, Mahgoun S．Diabetes mellitus in elderly[J]．Indian J Endocrinol Metab，2015，19(6)：744-752.

Please choose a citation manager

Content to export